Kraig Biocraft Laboratories Achieves Breakthrough In Recombinant Spider Silk Design Complexity
Kraig Biocraft Laboratories (OTCQB: KBLB) has announced a significant breakthrough in its genetic research program, successfully doubling the complexity and size of its spider silk gene insert package. This advancement aims to enhance the performance characteristics of their spider silk fibers, including strength, elasticity, and durability.
The company is pursuing a dual strategy: advancing research while maintaining focus on commercial production. CEO Kim Thompson emphasizes the potential of larger gene insert packages to unlock superior material characteristics, while COO Jon Rice confirms they remain on track for commercial-scale manufacturing and material sales this year.
The breakthrough is expected to impact applications across technical textiles, defense, and medical industries. Kraig Labs continues to position itself as a global leader in spider silk technology, balancing innovation with production to meet market demand for these bioengineered materials.
Kraig Biocraft Laboratories (OTCQB: KBLB) ha annunciato un'importante innovazione nel suo programma di ricerca genetica, raddoppiando con successo la complessità e le dimensioni del pacchetto di inserimento del gene della seta di ragno. Questo progresso mira a migliorare le caratteristiche prestazionali delle loro fibre di seta di ragno, inclusi forza, elasticità e durata.
L'azienda sta perseguendo una strategia duale: avanzare nella ricerca mantenendo l'attenzione sulla produzione commerciale. Il CEO Kim Thompson sottolinea il potenziale dei pacchetti di inserimento genico più grandi per sbloccare caratteristiche materiali superiori, mentre il COO Jon Rice conferma che rimangono sulla buona strada per la produzione su scala commerciale e la vendita di materiali quest'anno.
Si prevede che questa innovazione avrà un impatto sulle applicazioni nei tessuti tecnici, nella difesa e nell'industria medica. Kraig Labs continua a posizionarsi come leader globale nella tecnologia della seta di ragno, bilanciando innovazione e produzione per soddisfare la domanda di mercato per questi materiali bioingegnerizzati.
Kraig Biocraft Laboratories (OTCQB: KBLB) ha anunciado un avance significativo en su programa de investigación genética, logrando duplicar con éxito la complejidad y el tamaño de su paquete de inserción de genes de seda de araña. Este avance tiene como objetivo mejorar las características de rendimiento de sus fibras de seda de araña, incluyendo resistencia, elasticidad y durabilidad.
La empresa está siguiendo una estrategia dual: avanzar en la investigación mientras mantiene el enfoque en la producción comercial. El CEO Kim Thompson enfatiza el potencial de los paquetes de inserción de genes más grandes para desbloquear características materiales superiores, mientras que el COO Jon Rice confirma que siguen en camino hacia la fabricación a escala comercial y la venta de materiales este año.
Se espera que este avance impacte aplicaciones en textiles técnicos, defensa e industrias médicas. Kraig Labs continúa posicionándose como un líder global en tecnología de seda de araña, equilibrando la innovación con la producción para satisfacer la demanda del mercado de estos materiales bioingenierizados.
크레이그 바이오크래프트 연구소 (OTCQB: KBLB)는 유전자 연구 프로그램에서 중요한 돌파구를 발표하며, 거미 실크 유전자 삽입 패키지의 복잡성과 크기를 성공적으로 두 배로 늘렸습니다. 이 발전은 그들의 거미 실크 섬유의 성능 특성, 즉 강도, 탄력성 및 내구성을 향상시키는 것을 목표로 하고 있습니다.
회사는 연구를 진전시키는 동시에 상업 생산에 집중하는 이중 전략을 추구하고 있습니다. CEO 킴 톰슨은 더 큰 유전자 삽입 패키지가 우수한 물질 특성을 열 수 있는 잠재력을 강조하며, COO 존 라이스는 올해 상업 규모의 제조 및 자재 판매를 위한 계획이 순조롭게 진행되고 있다고 확인했습니다.
이번 돌파구는 기술 섬유, 방위 및 의료 산업 전반에 걸쳐 응용 프로그램에 영향을 미칠 것으로 예상됩니다. 크레이그 연구소는 이러한 생체 공학 재료에 대한 시장 수요를 충족하기 위해 혁신과 생산의 균형을 맞추며 거미 실크 기술의 글로벌 리더로 자리매김하고 있습니다.
Kraig Biocraft Laboratories (OTCQB: KBLB) a annoncé une avancée significative dans son programme de recherche génétique, ayant réussi à doubler la complexité et la taille de son paquet d'insertion de gène de soie d'araignée. Cette avancée vise à améliorer les caractéristiques de performance de leurs fibres de soie d'araignée, y compris la résistance, l'élasticité et la durabilité.
L'entreprise poursuit une stratégie double : faire avancer la recherche tout en maintenant un accent sur la production commerciale. Le PDG Kim Thompson souligne le potentiel des paquets d'insertion de gènes plus grands pour débloquer des caractéristiques matérielles supérieures, tandis que le COO Jon Rice confirme qu'ils restent sur la bonne voie pour la fabrication à l'échelle commerciale et la vente de matériaux cette année.
Cette avancée devrait avoir un impact sur les applications dans les textiles techniques, la défense et les industries médicales. Kraig Labs continue de se positionner comme un leader mondial dans la technologie de la soie d'araignée, équilibrant innovation et production pour répondre à la demande du marché pour ces matériaux bio-ingénierisés.
Kraig Biocraft Laboratories (OTCQB: KBLB) hat einen bedeutenden Durchbruch in seinem genetischen Forschungsprogramm bekannt gegeben, indem es erfolgreich die Komplexität und Größe seines Geneinschubpakets für Spinnenseide verdoppelt hat. Dieser Fortschritt zielt darauf ab, die Leistungsmerkmale ihrer Spinnenseidenfasern, einschließlich Stärke, Elastizität und Haltbarkeit, zu verbessern.
Das Unternehmen verfolgt eine duale Strategie: Forschung vorantreiben und gleichzeitig den Fokus auf die kommerzielle Produktion legen. CEO Kim Thompson betont das Potenzial größerer Geneinschubpakete, um überlegene Materialeigenschaften freizusetzen, während COO Jon Rice bestätigt, dass sie auf dem richtigen Weg zur kommerziellen Herstellung und Materialverkäufen in diesem Jahr sind.
Der Durchbruch wird voraussichtlich Auswirkungen auf Anwendungen in technischen Textilien, Verteidigung und Medizin haben. Kraig Labs positioniert sich weiterhin als globaler Marktführer in der Spinnenseidentechnologie und balanciert Innovation mit Produktion, um der Marktnachfrage nach diesen bioengineering Materialien gerecht zu werden.
- Breakthrough in genetic research doubles spider silk gene insert complexity
- On track for commercial production and sales in 2025
- Advancement may enhance product performance characteristics
- None.
Paving the Way for Advanced Material Performance
ANN ARBOR, Mich., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Kraig Labs" or "the Company"), a leading developer of spider silk-based fibers, today announced a significant breakthrough in its genetic research program. The Company's research team has successfully doubled the complexity and size of its spider silk gene insert package; a milestone expected to drive new advancements in material performance.
Building on its pioneering work in recombinant spider silk production, the Company’s latest achievement represents a major step forward in the development of next-generation fibers. By expanding the gene insert package, Kraig Labs aims to create more advanced silk materials with improved strength, elasticity, and durability—critical attributes for high-performance applications in technical textiles, defense, and medical industries.
"We believe that larger and more complex gene insert packages hold the potential to unlock superior material characteristics in our spider silk fibers," said Kim Thompson, CEO and Founder of Kraig Labs. "This breakthrough reinforces our leadership in biomaterials innovation and sets the stage for the next evolution of spider silk technology."
While this cutting-edge research progresses in the lab, Kraig Labs remains committed to bringing its revolutionary spider silk fibers to market. The Company's production team continues its focus on commercial-scale spider silk manufacturing, with targeted material sales into multiple markets. Kraig Labs expects this will be a pivotal year for industry integration of spider silk.
"Our production team is on track to deliver commercial quantities of our spider silk this year, even as our research team pushes the boundaries of what's possible in the lab," added the Company’s COO, Jon Rice. "We are strategically balancing innovation and production to meet the growing demand for our game-changing materials."
With its dual focus on both research and commercialization, Kraig Labs is solidifying its position as a global leader in spider silk technology. The Company remains dedicated to transforming the future of performance materials with bioengineered spider silk.
For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/76c6cb98-7391-4814-af4f-53305567c75e
https://www.globenewswire.com/NewsRoom/AttachmentNg/421bac64-c093-4ea0-897b-0e2559c8783b
FAQ
What is the latest breakthrough announced by Kraig Biocraft (KBLB) in spider silk development?
When does KBLB expect to begin commercial spider silk production?
What industries are targeted for KBLB's spider silk applications?
How will the new gene insert package breakthrough benefit KBLB's products?
